Abstract 328P
Background
For localized papillary renal cell carcinoma (PRCC), treatment guidelines generally recommend partial nephrectomy (PN) or radical nephrectomy (RN). However, there is limited long-term follow-up data available on outcomes following robot-assisted partial nephrectomy (RAPN) or robot-assisted radical nephrectomy (RARN) in PRCC patients. Therefore, we conducted a retrospective study to review the long-term outcomes of localized PRCC patients who underwent RAPN or RARN at our institution.
Methods
We conducted a retrospective analysis of patients who underwent robot-assisted laparoscopic partial nephrectomy or radical nephrectomy from December 2014 to October 2023. Eligibility criteria included unilateral primary tumors, with postoperative pathological diagnosis based on the 2022 WHO Classification of Tumours of the Urinary System and Male Genital Organs, Fifth Edition, confirming PRCC. Follow-up assessments included disease-free survival (DFS), recurrence, metastasis, and mortality outcomes.
Results
In our study, 142 eligible patients were included, comprising 114 (80.28%) who underwent RAPN, with 102 (89.47%) undergoing regular follow-up. Eighteen patients (19.72%) underwent RARN with 12 (66.67%) undergoing regular follow-up. All patients were diagnosed with PRCC according to the 2022 WHO Classification. The median follow-up duration was 4 years. Among RAPN patients, 101 had DFS, with no cases of recurrence, metastasis, and one death. Among RARN patients, 9 had DFS, with no cases of recurrence, one case of metastasis, and two deaths.
Conclusions
Our study underscores the superiority of robot-assisted laparoscopic partial nephrectomy RAPN over RARN in terms of DFS, with lower rates of metastasis and mortality in patients diagnosed with localized PRCC. These findings advocate for RAPN as the preferred surgical approach when feasible, offering improved prognostic outcomes for patients with PRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (82172777).
Disclosure
All authors have declared no conflicts of interest.